A lot higher volume of trades today, especially in ISDX, and by the looks of it mostly buys. Very little sign of selling. As we move in to next year, with a flow of new products conraining Fruitflow breaking cover, expectations will increase, not before time. Five years for a lab test concept to become firmly established as a commercial product is perhaps par for the course. True value for shareholders will then become apparent IMHO
That RNS was in line with anyone who has being observing this share would expect. SP will end close to yesterdays close. I thinlk the RNS for this time next year will be vital as revenue will be expected at that stage. Alf has more or less got it right imho regarding todays RNS in his 14.58 post. But this time next year we will need to see some form of revenue flow.
When we have all anticipated the financial situation, discussed at length for a long time now, what more can we say about it today. As expected, the investment in production capacity to go global has diverted revenues in the short term. Just a fact of a profit sharing agreement, short term profit foregone in order to generate much larger returns in future. A very simple and very wise policy. All long termers are with them on that score. The news that DSM are working on a further dozen new products is positive, up from seven at the AGM, each new product initiates another revenue stream, shares costs out over more volume, raises trade awareness of Fruitflow, and increases consumer education. As if that isnt enough positive news, we have even cut the wage bill again. By a quid !!
I have just read the full RNS and I don’t see what all the fuss is about. Stephen Moon to focus on SIS, no surprise there. Sufficient funds to cover operating the business until 2016, which does not include any possible revenues. Substantial money spent in establishing a commercial scale supply chain for powder manufacturing, but it had to be done. Costs are due to reduce, manufacturing is due to increase. DSM are going to hand over whatever they are contractually obligated to hand over to us, be it crumbs or millions. Provexis will rise or fall based on future sales, this RNS is not negative in my opinion.
it all sounded good to me moon gone which is not a bad thing 12 more products to go to market dsm invested in manufacturing plant they dont build plants to show a loss in tax return they seem to have every confidence in product everything is in place ready for the big push
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.